New drug targets Hard-to-Treat cancer mutation in early trial
NCT ID NCT06667544
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, RNK08954, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to find a safe and effective dose and see if the drug can shrink tumors or slow their growth. About 152 adults who have already tried standard treatments will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12D MUTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangxi Medical University Cancer Hospital
RECRUITINGNanning, Guangxi, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, China
-
Shanghai Chest Hospital
RECRUITINGShanghai, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.